FOXP3 and systemic lupus erythematosus: For the CD4+FOXP3+CD25+CD127− Treg cell profile, there were no significant variations among groups of patients with active SLE (36.38%, 4.70-61.80%), remission (28.12%, 3.12-63.83%) or healthy subjects (38.80%, 19.72-68.07%) (p>0.05) (Figure 1(c)).